Page 33 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

F-star Therapeutics, Inc : F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces first quarter 2021 financial results and provides a corporate update. Strengthens balance sheet with successful closing of $65 million public offering of common stock and; Received $9.2 million in net proceeds under its at-the-market equity offering program LAG-3 and PD-(L)1 co-targeting validation with LAG-3 validated in late-stage clinical trial as third checkpoint inhibitor pathway FS118 FS222 presentation at AACR on the importance of tuning both affinity and avidity for differentiation

United statesUnited kingdomHelen shikLindsey trickettDarlene deptula hicksEliot forsterEuropean patent officeNature communicationsDrug administrationCompany to host conference callHorizon technology finance corporationResearch developmentAmerican association for cancer researchMerck kgaTherapeutics incMerck kgaa

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE 17 May 2021, 21:05 GMT+10 COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuticals for PRS-342, a preclinical 4-1BB/GPC3 immuno-oncology bispecific; Pieris to receive $10 million upfront payment and is eligible to receive up to approximately $353 million in milestone payments , as well as tiered royalties and sublicense revenue share BOSTON, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin

United statesStephens yoderMaria kelmanDrug administrationPieris pharmaceuticalsCompany quarterly reports on formBoston pharmaceuticalsExchange commissionCompany annual report on formAmerican association for cancer researchSecurities exchangeBoston pharmaceuticals collaborationPieris pharmaceuticals incChief executive officerAstrazeneca collaborationAmerican association

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update ACCESSWIRE SON-1010, fully-human IL-12 configured using F HAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE / May 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ( Sonnet or the Company ), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended March 31, 2021 and provided a business update. Over the course of the quarter, we have made several advancements across our pipeline products, most notably of which are the completion of non-human primate (NHP) toxicology study of SON-080 and the completion of a repeat dose study of SON-1010 in NHPs, commented Pankaj Mohan, Ph.D., Founder and CEO. Additionally, we were thrilled to have our abstract detailing data from our NHP study of SON-1010 accep

United statesJay crossPankaj mohanRichard kenneyJalan ladaExchange commissionAmerican association for cancer researchSonnet biotherapeutics incSecurities exchangeSonnet biotherapeutics holdings incAmerican associationCancer researchAnnual meetingRecent corporate updatesNew life therapeuticsDiabetic peripheral neuropathy

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesAmerican association for cancer researchCalithera biosciences incSociety for immunotherapy of cancerPrnewswire antengene corporation limitedCorporation limitedCalithera biosciencesCancer researchAnnual meetingஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சிசமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய்நிறுவனம் வரையறுக்கப்பட்டவைபுற்றுநோய் ஆராய்ச்சிஆண்டு சந்தித்தல்

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United statesLaurence wattsMark voskoboynikRemy durandPamela hollandAlex sharifAmerican society of clinical oncologyAlpine immune sciencesAlpine immune sciences incExchange commissionAmerican association for cancer researchCorporate developmentGilmartin groupSecurities exchangeNucleus networkBusiness development